Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira Pena J, Badesch DB. Humbert M, et al. Among authors: badesch db. Eur Respir J. 2023 Jan 6;61(1):2201347. doi: 10.1183/13993003.01347-2022. Print 2023 Jan. Eur Respir J. 2023. PMID: 36041750 Free PMC article. Clinical Trial.
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr. Badesch DB, et al. Ann Intern Med. 2000 Mar 21;132(6):425-34. doi: 10.7326/0003-4819-132-6-200003210-00002. Ann Intern Med. 2000. PMID: 10733441 Clinical Trial.
Beraprost therapy for pulmonary arterial hypertension.
Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R; Beraprost Study Group. Barst RJ, et al. J Am Coll Cardiol. 2003 Jun 18;41(12):2119-25. doi: 10.1016/s0735-1097(03)00463-7. J Am Coll Cardiol. 2003. PMID: 12821234 Free article. Clinical Trial.
Prostanoid therapy for pulmonary arterial hypertension.
Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O, Barst RJ. Badesch DB, et al. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):56S-61S. doi: 10.1016/j.jacc.2004.02.036. J Am Coll Cardiol. 2004. PMID: 15194179 Free article. Review.
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, Humbert M, Rainisio M, Rubin LJ, Simonneau G. Sitbon O, et al. Among authors: badesch db. Thorax. 2005 Dec;60(12):1025-30. doi: 10.1136/thx.2005.040618. Epub 2005 Jul 29. Thorax. 2005. PMID: 16055621 Free PMC article.
Autoimmunity and pulmonary hypertension: a perspective.
Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Nicolls MR, et al. Among authors: badesch db. Eur Respir J. 2005 Dec;26(6):1110-8. doi: 10.1183/09031936.05.00045705. Eur Respir J. 2005. PMID: 16319344 Free article. Review.
Temporal trends and drug exposures in pulmonary hypertension: an American experience.
Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenhaim L, Constantine G. Walker AM, et al. Am Heart J. 2006 Sep;152(3):521-6. doi: 10.1016/j.ahj.2006.02.020. Am Heart J. 2006. PMID: 16923424
170 results